Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on innovative immunotherapies, announced the appointment of Dr. Eugene P. Kennedy as Chief Medical Officer. Dr. Kennedy brings over 15 years of experience in oncology and immuno-oncology, with a strong track record in clinical development and regulatory strategies. His prior roles include CMO positions at Galera Therapeutics, Innovative Cellular Therapeutics, Lumos Pharma, and NewLink Genetics. At Carisma, Dr. Kennedy will oversee clinical development, regulatory, and medical affairs to advance the company’s pipeline of engineered macrophages for cancer treatment. CEO Steven Kelly expressed confidence that Dr. Kennedy’s expertise would significantly impact the company’s clinical progress. Dr. Kennedy also highlighted his excitement about contributing to Carisma’s mission to develop transformative cancer therapies. Carisma Therapeutics is headquartered in Philadelphia and specializes in macrophage and monocyte cell engineering for immunotherapy.

Biopharmaceuticals, Healthcare, Venture Capital,United States, Philadelphia, PA

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer